Human medicines European public assessment report (EPAR): Veoza, fezolinetant, Status: Authorised
Overview On 12 October 2023, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Veoza, intended for the treatment of hot flushes (vasomotor …